NCT04537949View on ClinicalTrials.gov

A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

March 12, 2021

Study Completion Date

February 7, 2022

Conditions
Covid-19Protection Against COVID-19
Interventions
BIOLOGICAL

BNT162b3

Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost (P/B) regimen).

Trial Locations (2)

Unknown

Contract Research Organization, Berlin

Contract Research Organization, Mannheim

Sponsors

Lead Sponsor

BioNTech SE
All Listed Sponsors
lead

BioNTech SE

INDUSTRY